The UCLA ATLAS Biobank is a massive precision medicine initiative that integrates the electronic health records and genetic data of over 90,000 diverse participants. By moving beyond historically European-centric studies, researchers identified ancestry-specific disease risks and novel gene-phenotype associations across 36 distinct fine-scale population clusters. The study utilized both array genotyping and exome sequencing to uncover how common and rare genetic variants influence conditions like type 2 diabetes, cardiovascular disease, and chronic renal failure. Furthermore, the project highlights pharmacogenomic insights, such as how genetic background affects weight-loss responses to the drug semaglutide. Ultimately, these sources demonstrate that prioritizing ancestral diversity within a single health system leads to more equitable and effective personalized healthcare.

References:

• Haas R, Margolis M P, Wei A, et al. Advancing Precision Health Discovery in a Genetically Diverse Health System[J]. medRxiv, 2025: 2025.06. 11.25329386.